Rovalpituzumab 生物類似藥, 人 DLL3 單克隆抗體-Rovalpituzumab Biosimilar, Human DLL3 Monoclonal Antibody代理/參數(shù)/廠家-二抗-艾美捷科技有限公司

PRODUCT CENTER

二抗

產(chǎn)品中心

當前位置：首頁 > 產(chǎn)品中心 > 免疫學產(chǎn)品 > 二抗

中文名稱: Rovalpituzumab 生物類似藥, 人 DLL3 單克隆抗體

英文名字: Rovalpituzumab Biosimilar, Human DLL3 Monoclonal Antibody

供應商: Promab

產(chǎn)品貨號: PMB-B00063

產(chǎn)品報價: ￥詢價/1mg/5mg/20mg

產(chǎn)品說明書: 點擊查看

購買方式: 90%產(chǎn)品中國有現(xiàn)貨庫存。銀行轉(zhuǎn)賬、電匯、支票、現(xiàn)金，在線支付寶及網(wǎng)銀支付，或直接與我們電話聯(lián)系400-6800-868

產(chǎn)品新聞

背景資料: What is rovalpituzumab biosimilar research grade? Rovalpituzumab is a humanized IgG1-kappa monoclonal antibody against the human Delta-like 3 protein (DLL3), which is an atypical Notch ligand that has been implicated in regulation of cell development and cell fate decisions, and is a downstream target of achaetescute homolog-1 (ASCL1), suggesting its role in neuroendocrine tumorigenesis. DLL3 is expressed in more than 80% of patients with small-cell lung cancer (SCLC) and other neuroendocrine tumors, but has little to no expression in normal tissues or non-neuroendocrine tumor types. DLL3 expression appears to be stable over time in SCLC tumors pre- and post-chemotherapy. Although DLL3 is mostly found within the Golgi apparatus under physiological conditions, it may reach the cell surface in case of overexpression and lead to Notch inhibition in cis. Rovalpituzumab tesirine (Rova-T) is a first-in-class antibody–drug conjugate (ADC) against DLL3, and composed of SC16, a humanized IgG1 antibody against DLL3, conjugated to the cytotoxic pyrrolobenzodiazepine (PBD) dimer D6.5 (SC-DR002) via a protease-cleavable linker. Rova-T selectively binds to DLL3 on target-expressing cells, is internalized, and upon proteolytic cleavage releases the toxin. PBD dimers then bind to the DNA minor groove where they form covalent adducts causing stalling of the replication forks, cell-cycle arrest at the G2–M boundary, and apoptosis. Rovalpituzumab biosimilar uses the same protein sequences as the therapeutic antibody rovalpituzumab.